Figure 2From: A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients Incidence of peripheral oedema in patients treated with lumiracoxib and rofecoxib (safety population). The incidence of peripheral oedema at Week 6. Pairwise comparisons tested at the two-sided 5% significance level. p-value computed using Fisher's exact test. OA, osteoarthritis.Back to article page